Bionano GenomicsBNGOW 64 FCF Yield % is -143.73 as of Jun. 30, 2026. GuruFocus rates BNGOW with a GF Score™ of 64/100. The stock has 3 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Bionano Genomics ranks worse than 96.72% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Bionano Genomics's FCF Yield % or its related term are showing as below:
BNGOW'
s FCF Yield % Range Over the Past 10 Years
Min: -1446.03 Med: -73.96 Max: -1.47
Current: -143.73
During the past 10 years, the highest FCF Yield % of Bionano Genomics was -1.47%. The lowest was -1446.03%. And the median was -73.96%.
BNGOW's FCF Yield % is ranked worse than 96.72% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: -0.385
vs BNGOW: -143.73
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Bionano Genomics FCF Yield % Related Terms
Bionano Genomics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Bionano Genomics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Bionano Genomics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionano Genomics (BNGOW) has a FCF Yield % of -143.73 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Bionano Genomics and its competitors. According to the industry distribution chart, Bionano Genomics ranks #826 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 96.7%.
Is Bionano Genomics' FCF Yield % too high?
Bionano Genomics' current FCF Yield % is -143.73. Based on the distribution chart, Bionano Genomics ranks #826 out of 854 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bionano Genomics has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' FCF Yield % compare to UEEC and CUPR?
According to the Medical Devices & Instruments industry distribution chart, Bionano Genomics ranks #826 out of 854 companies for FCF Yield %. This places Bionano Genomics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Bionano Genomics and its competitors. Bionano Genomics's current FCF Yield % is -143.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Bionano Genomics (BNGOW) has a current FCF Yield % of -143.73. The current FCF Yield % is -143.73. Bionano Genomics' overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Bionano Genomics (BNGOW), the current FCF Yield % is -143.73 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
64GF Score
Get the complete analysis for BNGOW
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNGOW has been successfully added to your 
